Daniel J. Mangless nominated Board candidates to Zevra Therapeutics (ZVRA)
Key Summary: Daniel J. Mangless, who successfully elected three nominees to the Board at the 2023 AGM, filed proxy materials on April 10, 2025, to nominate two candidates for the 2025 AGM.
Market Cap: $355 million | Zevra Therapeutics, Inc., a rare disease therapeutics company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
On April 10, 2025, Daniel J. Mangless filed proxy materials nominating two candidates for election to the Board at the 2025 AGM.
Background
On March 3, 2023, Daniel J. Mangless (2.3%) nominated three director candidates for election to the Board at the 2023 AGM. Source
On March 16, 2023, Daniel J. Mangless filed proxy materials seeking support for his nominees.
At the AGM held on April 25, 2023, shareholders elected Daniel J. Mangless nominees: John B. Bode, Douglas W. Calder, and Corey Watton to the Board.
Member discussion